To date there have been no formal studies of the cost-effectiveness of magnetic resonance spectroscopy. Cost-effectiveness analysis was conducted by utilizing a decision-analytic model that compared MRS and standard of care to standard of care alone for recurrent glioma and necrosis differentiation. Our results showed that performing MRS was highly cost-effective with incremental cost-effectiveness ratios of -$98,978, -$50,666 and -$41,349 per quality-adjusted life-years over 5-year, 10-year and lifetime horizons. At the willingness-to-pay threshold of $50,000, performing MRS was more cost-effective with certainty of 96% to 97% over those time-horizons. MRS should be considered reimbursable by policy makers.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords